SAFE AND EFFECTIVE USE OF BARICITINIB AND REMDESIVIR IN HOSPITALIZED PATIENTS WITH CORONAVIRUS (COVID-19)

Course overview

BARICITINIB IS A MEDICATION TRADITIONALLY USED IN THE MANAGEMENT AND TREATMENT OF RHEUMATOID ARTHRITIS. HOWEVER, WITH THE RECENT ADVENT OF THE COVID-19 GLOBAL PANDEMIC, SEVERAL AGENTS HAVE BEEN EVALUATED FOR THE MANAGEMENT OF THIS DISEASE. BARICITINIB IS IN THE JAK INHIBITOR CLASS OF MEDICATIONS. THIS ACTIVITY REVIEWS THE INDICATIONS, ACTION, AND CONTRAINDICATIONS FOR THE CONCURRENT USE OF REMDESIVIR AND BARICITINIB AS VALUABLE AGENTS IN THE MANAGEMENT OF COVID-19. THIS ACTIVITY WILL HIGHLIGHT THE MECHANISM OF ACTION, ADVERSE EVENT PROFILE, AND OTHER KEY FACTORS LIKE INDICATIONS AND CONTRAINDICATIONS, DOSING, PHARMACODYNAMICS, PHARMACOKINETICS, PERTINENT FOR MEMBERS OF THE INTERPROFESSIONAL TEAM IN THE MANAGEMENT OF PATIENTS WITH COVID-19 AND RELATED CONDITIONS